retatrutide clinical trial results weight loss efficacy Results: 24% in 48 Weeks Retatrutide: A Triple Agonist Shaping
Description
This isnt an anti-Ozempic article
Significant improvement over single agonist but still lacks the energy expenditure component
Fatigue, reported in 8% to 12% of participants, is worth noting because its source matters
D'Alessio declares an association with the following companies: Amylin (research support, consulting), Johnson and Johnson (research support, scientific advisory boards, consulting), MannKind (research support), Merck (consulting), Novo Nordisk (scientific advisory board), Sanofi-Aventis (research support), Takeda (consulting)
